Refine by
Therapeutic Benefit Articles & Analysis: Older
35 news found
By utilizing the unique properties of hydrogel and microneedles, we have developed a system that can significantly enhance the delivery of therapeutic agents to patients." The hydrogel microneedle patch technology has been subjected to extensive research and testing by CD Formulation's team to prove its accuracy and efficacy. ...
“We are thrilled to welcome Tom and Marc to the Tris Pharma executive team, and I am confident that their expertise will play a critical role in helping us continue to develop and commercialize differentiated approaches that enhance therapeutic benefit and optimize outcomes for patients,” said Ketan Mehta, founder and chief executive officer of Tris ...
Caroline Man Xu, Co-founder and CEO of ViGeneron said: “The evolution of medicines from small molecules to proteins has driven increased therapeutic benefits in the past; the next generation of gene therapies holds tremendous promise for patients. ...
” Human abuse potential studies are required prior to FDA approval in therapeutic classes with high abuse potential and are designed as phase 1 studies. ...
“We’re also excited to explore partnerships with biopharma companies looking to benefit from the mapping of secreted proteins to other therapeutic focus ...
“Early diagnosis of ASD is important because the benefit of therapeutic intervention is greater the earlier it is begun. ...
In the future, we hope this type of biomarker response will help predict a therapeutic benefit long before clinical benefits can be measured.” Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. ...
FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases (a condition with a prevalence of less than 200,000 in the U.S.), and to provide incentives to the subsequent development, registration and commercialization to designated drugs. ...
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival ...
The Cellworks platform analyzes the impact of specific therapies on the patient’s personalized disease model and generates a SingulaTM biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict low to high therapeutic benefit. About Cellworks Group Cellworks Group, Inc. is a world leader in Genomic Biosimulation Services for ...
The myCare-203A study found that the personalized approach of Cellworks SingulaTM TRI produces a more precise therapeutic decision guide for patients with NSCLC.” “There are multiple approved drugs for treating NSCLC, which makes selecting the most efficacious treatment for each patient more complicated,” said Dr. ...
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, and Brightseed, creators of Forager®, a pioneering artificial intelligence platform that illuminates the connections between nature and human health, have entered a strategic research collaboration to screen plant compounds to identify and validate active ...
Human iPSc's are genetically reprogrammed to differentiate into a wide array of human cell and tissue types, possess the ability to proliferate almost indefinitely in culture, and represent a single source of cells that could be used to replace those lost to damage or disease. Beyond the therapeutic benefits offered by iPSC, the next generation iPScelzTM pipeline ...
In addition to enhancing the differentiation and yield of immune cells within the manufacturing process, our RACR™ system should bring therapeutic benefit to patients, allowing for safe in vivo engraftment and persistence of tumor-killing cells without requirements for toxic lymphodepleting ...
It was also revealing that there were no patient withdrawals throughout the study. The therapeutic benefits associated with ILB administration decreased 3-4 weeks after the last dosage. ...
Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. ...
“We believe by targeting the LILRB4 checkpoint, IO-202 may reverse the immunosuppressive effects of tumor associated monocytic myeloid cells, enhance dendritic cell function, and promote T cell activation – thereby, unleashing the antitumor activities of the immune system and increasing the therapeutic benefit of T cell checkpoint inhibitors. We look ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. ...
With it, NOI/NEC has acquired the rights to an attractive delivery platform with broad therapeutic potential in oncology and other areas,. Following this acquisition, we expect to initiate the first clinical study delivering personalized neoantigens during 2022, which is an important milestone. ...
This mode of administration further contributes to its favorable therapeutic and safety profile in addition to its general ease of use. Dr. Bruno Maranda, Chief Medical Officer of Immune Biosolutions commented: “One should not underestimate the therapeutic and commercial advantages provided by a self-administered therapeutic solution ...